Persica News
The latest news & press releases from Persica Pharmaceuticals
Positive Clinical Data for PP353 Published in The Lancet’s eClinicalMedicine
Persica Pharmaceuticals’ Positive Clinical Data for PP353 Treatment of Chronic Low Back Pain Published in The Lancet’s eClinicalMedicine
Talking non-opioid pain therapies with the FT
In November 2025, our CEO Steve Ruston participated in a fireside chat with FT US Pharmaceutical Correspondent Patrick Temple-West, discussing how
Q&A with Joshua Hirsch, Neurointerventionalist at Massachusetts General Hospital and Professor at Harvard Medical School
Please introduce yourself and tell us what you do I’m a neurointerventionalist at Massachusetts General Hospital and a professor at Harvard Medical
Persica strengthens global IP portfolio with EU patent granted for PP353
London, UK, 11 June 2025 – Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative
Persica Pharmaceuticals in the news 2025
During 2025, Persica has been featured in a number of publications across national and healthcare trade media following the announcement of positive
Q&A with Lloyd Czaplewski, Ph.D., CSO of Persica Pharmaceuticals
Q1) Can you tell us a bit about your background? How did you become involved in Persica? Through degree, Ph.D. and postdoc I was a microbial
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic
Q&A with Steve Ruston, Chief Executive Officer
Q&A with Steve Ruston, Chief Executive Officer What is Persica’s mission? Our mission is to help people suffering with chronic Low Back Pain
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025
Persica Pharmaceuticals’ research published in Journal of Orthopaedic Research Spine ahead of anticipated clinical data in 2025 Persica is
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March
Persica Pharmaceuticals Announces Collaboration with BackCare
Persica Pharmaceuticals Announces Collaboration with BackCare London, UK, 24 August 2022 – Persica Pharmaceuticals Ltd, a clinical stage
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons
Peter Hamlyn, Founder and Director of Persica Pharmaceuticals will be presenting at the British Association of Spine Surgeons London, UK, 24